Turn Therapeutics Inc. (TTRX) Stock Score, Valuation & Financial Research

Turn Therapeutics Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for TTRX

Turn Therapeutics Inc. does not currently have a complete Wall Street Score. The stored market price is USD 13.35. These figures are a research snapshot, not a buy or sell recommendation.

What Turn Therapeutics Inc. does

Turn Therapeutics Inc., officially known as Global Health Solutions, Inc., is a pharmaceutical enterprise dedicated to developing treatments for conditions affecting the skin, nails, and eyes. The company utilizes a proprietary drug delivery system engineered to effectively permeate skin and nail tissues. This advanced technology is integrated into their solutions for both acute and chronic wound care, specifically designed to help combat antibiotic resistance. Consequently, these products empower healthcare institutions to effectively manage a broad spectrum of dermatological challenges, encompassing everything from sudden injuries and persistent wounds to general skin ailments and specific dermatoses. Global Health Solutions, Inc. was established in 2015 and maintains its headquarters in Westlake Village, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Turn Therapeutics operates a business model focused on the clinical development of pharmaceutical candidates while licensing or selling medical device products through commercial partners. This strategy is designed to minimize internal capital commitments and cash burn by leveraging external contractors and vendors for operational execution.

Products and services

  • The company develops non-systemic, non-biologic topical immunomodulators for inflammatory skin diseases, with a lead program (GX-03) in clinical development for eczema and onychomycosis.

Customer types

Commercial partners for medical devices.

Suppliers, materials and equipment

  • Contractors and vendors — The company utilizes various unnamed contractors and vendors to support its clinical development and operational activities. Source

Business relationships and partnerships

  • MiMedx — The company maintains a license agreement with MiMedx for the commercialization of medical device products. Source

Business strengths to evaluate

  • Strategic business model designed to minimize cash burn Source

Business risks and research considerations

  • Dependence on commercial partners for medical device sales Source
  • Risks associated with clinical development of pharmaceutical candidates Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

TTRX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 13.35
Market capitalization:
397.62M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -8.45M
Free cash flow:
USD -2.72M
Cash:
USD 10.29M
Total debt:
USD 6.12M
EPS:
USD -0.29

What stands out

  • Free cash flow is USD -2.72M, negative for the stored period.
  • The balance sheet shows USD 10.29M of cash versus USD 6.12M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 4.17M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for TTRX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can TTRX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is TTRX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for TTRX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of TTRX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research TTRX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.